Loading...
•
Jun 30, 2022
Arvinas Q2 2022 Earnings Report
Reported second quarter financial results and provided a corporate update.
Key Takeaways
Arvinas reported financial results for the second quarter ended June 30, 2022. The company is on track to initiate two pivotal programs with ARV-471 in metastatic breast cancer in the second half of this year and has a clear development pathway for bavdegalutamide in molecularly defined metastatic castration-resistant prostate cancer. The company is preparing to initiate its Phase 2 trial with ARV-766 by end of year.
Met with the FDA to discuss the potential for an accelerated approach for bavdegalutamide based on a single arm Phase 2 trial and a confirmatory Phase 3 trial for full approval.
Believes a randomized, pivotal Phase 3 trial provides the best opportunity to enable simultaneous global regulatory submissions for bavdegalutamide.
Finalized an agreement with Foundation Medicine to develop the FoundationOne®Liquid CDx as a companion diagnostic for use with bavdegalutamide.
Appointed John Northcott to newly created position of Chief Commercial Officer, effective August 1, 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...